The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

08-Feb-2018 | Source : Cellectar Biosciences | Visits : 4491
MADISON, Wis. - Cellectar Biosciences, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announced in a press release that the United States Patent and Trademark Office has issued a notice of allowance for US Patent Application No. 15/095,641, entitled "Alkylphosphocholine Analogs for Multiple Myeloma Imaging and Therapy," which covers a method of use for CLR 131, the company's lead radiotherapeutic Phospholipid Drug Conjugate™ (PDC™) in multiple myeloma (MM). 

CLR 131 is Cellectar's investigational compound under development for a range of orphan designated cancers. CLR 131 utilizes the company's patented PDC tumor targeting delivery platform to deliver the cytotoxic radioisotope iodine-131 directly to tumor cells. CLR 131 is currently being evaluated in a Phase 1 clinical trial in patients with relapse or refractory MM, as well as in a Phase 2 clinical trial for relapsed or refractory MM and select relapsed or refractory lymphomas. The US Food and Drug Administration has granted orphan drug designation for CLR 131 in the treatment of MM.

"This patent allowance enhances our intellectual property estate and underscores the novelty of CLR 131 for the treatment of multiple myeloma, a life-threatening disease with high unmet medical need," said James Caruso, chief executive officer of Cellectar Biosciences.  "Importantly, upon issuance, this patent will extend our coverage into the mid-2030s."

Related Articles